

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GOCABRBEV

Page 1 of 2

DOCTOR'S	S ORDERS	Htcm	Wtk	g BSA	m²	
REMINDER: PI	ease ensure drug allergies a	and previous bleomy	cin are documen	ted on the Alle	rgy & Alert Form	
DATE:		oe given:	C	cycle #:		
Date of Previous Cycle:						
☐ CBC & Diff, May proceed wit	ent week(s) platelets day of treatment h doses as written, if within 72 x 10 ⁹ /L, BP <u>less than or equ</u>					
Dose modification for:						
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm						
dexamethasone 8 mg or 12 mg (select one) PO 30 to 60 minutes prior to CARBOplatin						
AND select [ondansetron 8 mg PO	30 to 60 minutes prior	to CARBOplatin			
ONE of the	aprepitant 125 mg PO 30 to 60 minutes prior to CARBOplatin, and					
following: [ondansetron 8 mg PO 30 to 60 minutes prior to CARBOplatin					
	netupitant-palonosetro	n 300 mg-0.5 mg PO	30 to 60 minutes p	orior to CARBO	platin	
If additional antiemetic required:						
☐ OLANZapine	• ☐ 2.5 mg or ☐ 5 mg or ☐	10 mg (select one) Po	O 30 to 60 minutes	prior to CARB	Oplatin	
☐ Other:						
	** Have Hypersensit	ivity Reaction Medication	ons and Protocol A	vailable**		
CHEMOTHERAPY:						
PACLitaxel NAB (ABRAXANE) 260 mg/m² x BSA =mg ☐ Dose Modification:% =mg IV over 30 minutes (in empty sterile PVC, non-PVC or non-DEHP bag and tubing; use tubing with 15 micron filter)						
☐ Dose Mod	UC 6 or 5 (circle one) x (GF ification:% = 50 mL NS over 30 minutes.		mg			
Blood pressure measurement pre-bevacizumab dose.						
bevacizumab 7.5 mg/kg x kg = mg						
IV in 100 mL NS over 15 minutes (first infusion over 1 hour).						
OR	·					
bevacizumab 18 IV in 100 to 25	5 mg/kg x kg = 0 mL NS over 30 minutes (firs	mg st infusion over 1 hour)	ı.			
Blood pressure n	neasurement post-bevacizum	nab infusion for first 3 c	ycles.			
Pharmacy to s	select bevacizumab brand as per	Provincial Systemic The	rapy Policy III-190			
Drug	Brand (Pharmacist to comp	olete. Please print.)	Pharmacist In	nitial and Date		
bevacizumab						
DOCTOR'S SI	GNATURE:			I SIG	NATURE:	
				l UC	:	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GOCABRBEV

Page 2 of 2

DOCTOR'S ORDERS					
DATE:					
RETURN APPOINTMENT ORDERS					
Return in three weeks for Doctor and Cycle					
Last Treatment. Return in week(s).					
CBC & Diff, platelets, creatinine, laboratory urinalysis or urine dipstick for protein prior to next cycle.					
☐ CBC & Diff, platelets on Day 14.					
☐ 24 h urine for total protein within 3 days prior to next bevacizumab dose if 2+ or 3+ dipstick or greater than or equal to 1 g/L laboratory urinalysis for protein					
☐ INR weekly ☐ INR prior to next cycle					
Prior to next cycle, if clinically indicated:					
☐ Bilirubin ☐ Alk Phos ☐ GGT ☐ ALT ☐ LDH					
☐ Tot Prot ☐ Albumin ☐ CA 15-3 ☐ CA 125 ☐ CA 19-9 ☐ CEA ☐ SCC					
☐ Refer to Hereditary Cancer Program (see accompanying referral form)					
☐ Other tests:					
Consults:					
☐ See general orders sheet for additional requests.					
DOCTOR'S SIGNATURE:	SIGNATURE:				
	nc.				